Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: Where do we stand?

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 283-287

  Cacoub, P ^a   Delluc, A ^b   Saadoun, D ^b   Landau, D A ^b   Sene, D ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD20 ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MEMBRANE PROTEIN; PEGINTERFERON ALPHA; RIBAVIRIN; RITUXIMAB;

ARTERY THROMBOSIS; ARTICLE; B LYMPHOCYTE; BRADYCARDIA; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; MONOTHERAPY; PANNICULITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; SERUM SICKNESS; SIDE EFFECT; VASCULITIS; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CRYOGLOBULINEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULITIS;

EID: 39549109812     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.065565     Document Type: Article

References (25)

1. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308.
2. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
3. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum 1999;42:2204-12.
4. Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: a review. Metab Brain Dis 2004;19:357-81.
5. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
6. Cacoub P, Saadoun D, Sene D, Limal N, Piette JC. Treatment of hepatitis C virus-related systemic vasculitis. J Rheumatol 2005;32:2078-82.
7. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alpha-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005;52:911-5.
8. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-8.
9. Zaja F, De Vita S, Russo D, Michelutti A, Fanin R, Ferraccioli G, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum 2002;46: 2252-4.
10. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4.
11. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
12. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.
13. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61.
14. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, et al. Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2003;62:1230-3.
15. Ghobrial IM, Uslan DZ, Call TG, Witzig TE, Gertz MA. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenstrom macroglobulinemia does not indicate failure of response. Am J Hematol 2004;77:329-30.
16. Ghijsels E, Lerut E, Vanrenterghem Y, Kuypers D. Anti-CD20 monoclonal antibody (rituximab) treatment for hepatitis C-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure. Am J Kidney Dis 2004;43:e34-8.
17. Catuogno M, Rezai S, Priori R, Magrini L, Valesini G. Serum sickness associated with rituximab in a patient with hepatitis C virus-related mixed cryoglobulinaemia. Rheumatology (Oxford) 2005;44:406.
18. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80:1560-4.
19. Koukoulaki M, Abeygunasekara SC, Smith KG, Jayne DR. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab. Nephrol Dial Transplant 2005;20:213-6.
20. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford) 2005;44:410-1.
21. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006;45:842-6.
22. Cai FZ, Ahem M, Smith M. Treatment of cryoglobulinemia associated peripheral neuropathy with rituximab. J Rheumatol 2006;33:1197-8.
23. Saadoun D, Bieche I, Maisonobe T, Asselah T, Laurendeau I, Piette JC, et al. Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy. Arthritis Rheum 2005;52:2917-25.
24. Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2005;16:1675-82.
25. Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006;30(Suppl 1):S16-21.